Greenphire and Ernst & Young Announce Strategic Partnership
Greenphire, the leading provider of payment technologies for the clinical trials industry, today announce the launch of a strategic partnership with Ernst & Young.
Greenphire, the leading provider of payment technologies for the clinical trials industry, today announced the launch of a strategic partnership with Ernst & Young. The partnership will combine Greenphire’s industry leading eClinicalGPS technology with the global intellectual property and expertise of Ernst & Young’s advisory practice for clients in the pharmaceutical industries.
Within the scope of the partnership, Greenphire’s clients will have access to specialists within Ernst & Young’s global consulting and advisory practice that focuses on global HCP transparency regulatory compliance (e.g. – The US Sunshine Act). This relationship will increase the strength of Greenphire’s eClinicalGPS technology by giving clients the ability to leverage Ernst & Young’s market leading advisory practice in concert with Greenphire’s market leading payment and data aggregation technology. Ernst & Young’s advisory practice will further assist Greenphire’s clients to comply with 75+ transparency regulations globally.
Additionally, Ernst & Young’s extensive proprietary research will be routed into a new Greenphire technology solution. The technology, currently in development, will be a first-of-its-kind, web-based SaaS solution to manage and track all transactional interactions between pharmaceutical companies and HCPs, including cash transactions and transfers of value, on a global basis across all aspects of pharmaceutical operations.
Sam Whitaker, co-founder and CEO of Greenphire, comments: "We are delighted to work with Ernst & Young in what is sure to be an industry-changing partnership. Global transparency regulations are constantly evolving, and our clients are very much in need of a reliable source of information on how to adjust their processes to remain compliant. We are very excited to be able to offer them access to an incredible resource such as Ernst & Young.”
Martin Holyoake, Partner at Ernst & Young said: “We are proud to be working with Greenphire to help ensure that clients successfully navigate the complicated legislative landscape and deliver value. The deep technical knowledge and grounded relationships formed as a result of our long standing presence in this sector will help clients translate regulation, meet their obligations and gain real insight. We look forward to working with Greenphire to bring tangible benefits to our clients.”
For further information on Greenphire and its innovative solutions please email: [email protected], call +1 215-609-4640 or visit www.greenphire.com
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
